1-12 of 12
Michael R. Grever
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma

Available to Purchase
Douglas W. Sborov, Gerard J. Nuovo, Andrew Stiff, Thomas Mace, Gregory B. Lesinski, Don M. Benson, Jr, Yvonne A. Efebera, Ashley E. Rosko, Flavia Pichiorri, Michael R. Grever, Craig C. Hofmeister
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5946–5955.
https://doi.org/10.1158/1078-0432.CCR-14-1404
Published: 30 November 2014
View articletitled, A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
Open the PDF for A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol

Available to Purchase
Jia Ji, Diane R. Mould, Kristie A. Blum, Amy S. Ruppert, Ming Poi, Yuan Zhao, Amy J. Johnson, John C. Byrd, Michael R. Grever, Mitch A. Phelps
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1269–1280.
https://doi.org/10.1158/1078-0432.CCR-12-1092
Published: 03 March 2013
View articletitled, A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Open the PDF for A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol in another window
Includes: Supplementary data
Journal Articles

Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol

Available to Purchase
Lapo Alinari, Courtney J. Prince, Ryan B. Edwards, William H. Towns, Rajeswaran Mani, Amy Lehman, Xiaoli Zhang, David Jarjoura, Li Pan, A. Douglas Kinghorn, Michael R. Grever, Robert A. Baiocchi, David M. Lucas
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4600–4611.
https://doi.org/10.1158/1078-0432.CCR-12-0839
Published: 30 August 2012
View articletitled, Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol
Open the PDF for Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol in another window
Journal Articles

Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

Available to Purchase
Janet E. Dancey, Kevin K. Dobbin, Susan Groshen, J. Milburn Jessup, Andrew H. Hruszkewycz, Maria Koehler, Ralph Parchment, Mark J. Ratain, Lalitha K. Shankar, Walter M. Stadler, Lawrence D. True, Amy Gravell, Michael R. Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1745–1755.
https://doi.org/10.1158/1078-0432.CCR-09-2167
Published: 14 March 2010
View articletitled, Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
Open the PDF for Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents in another window
Journal Articles

Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Available to Purchase
Rebecca B. Klisovic, William Blum, Xiaohui Wei, Shujun Liu, Zhongfa Liu, Zhiliang Xie, Tamara Vukosavljevic, Cheryl Kefauver, LeNguyen Huynh, Jiuxia Pang, James A. Zwiebel, Steven Devine, John C. Byrd, Michael R. Grever, Kenneth Chan, Guido Marcucci
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3889–3895.
https://doi.org/10.1158/1078-0432.CCR-08-0109
Published: 16 June 2008
View articletitled, Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Open the PDF for Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Weekly Oxaliplatin Followed by Paclitaxel in Patients with Solid Tumors

Available to Purchase
Tanios S. Bekaii-Saab, Jing Liu, Kenneth K. Chan, Stanley P. Balcerzak, Percy S. Ivy, Michael R. Grever, Eric H. Kraut
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (11): 3434–3440.
https://doi.org/10.1158/1078-0432.CCR-07-4903
Published: 02 June 2008
View articletitled, A Phase I and Pharmacokinetic Study of Weekly Oxaliplatin Followed by Paclitaxel in Patients with Solid Tumors
Open the PDF for A Phase I and Pharmacokinetic Study of Weekly Oxaliplatin Followed by Paclitaxel in Patients with Solid Tumors in another window
Journal Articles

Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity

Available to Purchase
Syed-Rehan A. Hussain, Carolyn M. Cheney, Amy J. Johnson, Thomas S. Lin, Michael R. Grever, Michael A. Caligiuri, David M. Lucas, John C. Byrd
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2144–2150.
https://doi.org/10.1158/1078-0432.CCR-06-2294
Published: 02 April 2007
View articletitled, Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity
Open the PDF for Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity in another window
Journal Articles

HDAC Inhibitors and Cardiac Safety

Available to Purchase
Manisha H. Shah, Miguel A. Villalona-Calero, Guido Marcucci, John C. Byrd, Michael R. Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 1068.
https://doi.org/10.1158/1078-0432.CCR-06-2380
Published: 08 February 2007
View articletitled, HDAC Inhibitors and Cardiac Safety
Open the PDF for HDAC Inhibitors and Cardiac Safety in another window
Journal Articles

Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia

Available to Purchase
Yvette L. Kasamon, Ian W. Flinn, Michael R. Grever, Louis F. Diehl, Elizabeth Garrett-Mayer, Steven N. Goodman, Margaret S. Lucas, John C. Byrd
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (23): 8413–8417.
https://doi.org/10.1158/1078-0432.CCR-05-1612
Published: 01 December 2005
View articletitled, Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia
Open the PDF for Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia in another window
Journal Articles

Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805

Available to Purchase
John C. Byrd, Bercedis L. Peterson, Janice Gabrilove, Olatoyosi M. Odenike, Michael R. Grever, Kanti Rai, Richard A. Larson, the Cancer and Leukemia Group B
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (11): 4176–4181.
https://doi.org/10.1158/1078-0432.CCR-04-2276
Published: 01 June 2005
View articletitled, Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805
Open the PDF for Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805 in another window
Journal Articles

Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2: A Preclinical and Phase I Study

Available to Purchase
Charles F. Eisenbeis, Andrew Grainger, Beth Fischer, Robert A. Baiocchi, Lester Carrodeguas, Sameek Roychowdhury, Lei Chen, Amy L. Banks, Thomas Davis, Donn Young, Nicole Kelbick, Julie Stephens, John C. Byrd, Michael R. Grever, Michael A. Caligiuri, Pierluigi Porcu
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6101–6110.
https://doi.org/10.1158/1078-0432.CCR-04-0525
Published: 24 September 2004
View articletitled, Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2: A Preclinical and Phase I Study
Open the PDF for Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2: A Preclinical and Phase I Study in another window
Journal Articles

Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia

Available to Purchase
Steven D. Gore, Li-Jun Weng, William D. Figg, Suoping Zhai, Ross C. Donehower, George Dover, Michael R. Grever, Constance Griffin, Louise B. Grochow, Anita Hawkins, Kathleen Burks, Yelena Zabelena, Carole B. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (4): 963–970.
Published: 01 April 2002
View articletitled, Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia
Open the PDF for Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia in another window